News

Today, LGC Clinical Diagnostics, a business unit of LGC, announced the acquisition of Kova International, Inc. (Kova), a leading developer and manufacturer of in vitro urinalysis and toxicology quality control products for clinical laboratories

LGC today announced the appointment of Dr Mehrdad Tabrizi as Executive Vice President and General Manager for LGC Axolabs.

Five more soldiers who fell at the Battle of Fromelles more than 100 years ago have been identified using DNA analysis performed by LGC.

The first step in a partnership between the University of Leeds and the NML, the laboratory was launched on Friday, 31 March 2023 at a special event hosted Nexus, which features talks from Professors Julian Braybrook and Nick Plant, as well as a visit from the Mayor of West Yorkshire Tracy Brabin.

Leading manufacturer and supplier of analytical reference standards greatly complements LGC's current offering

After ten years with LGC, initially as Chief Executive Officer and most recently as Non-Executive Chair, Tim Robinson has announced that, as planned, he will be retiring from LGC to focus on public service and philanthropy.

Update for the half year ended 30 September 2022

LGC's first ESG report using GRI Standards, the most widely used sustainability reporting framework

Australians identified by LGC's ongoing DNA work concerning remains discovered at Fromelles, northern France

Roadmap to support the measurements associated with infectious disease and future pandemic readiness has recently been published

Facility will serve as home of The Native Antigen Company and an advanced workflow applications laboratory for LGC Biosearch Technologies

This is LGC’s second ESG report using the Global Reporting Initiative (GRI) Standards, the most widely used sustainability reporting framework globally.